Appili's Covid-19 oral antiviral fails PhIII trial; Oncology biotech Ankyra raises $45M in Series B
Appili Therapeutics’s investigational oral antiviral Avigan/Reeqonus failed in a Phase III trial, the biotech said in a statement this morning.
The Nova Scotia biotech’s PRESECO trial, which enrolled more than 1,200 patients to test a treatment for mild-to-moderate Covid-19, did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery.
Additional analyses of the trial data are ongoing, according to the biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.